Evidence map›Paper›PMID 38228856›Full record

ArticleDiscover oncology2024

Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype.

Mengting Zhu, Valentina Rovella, Manuel Scimeca, Alessandro Mauriello, Yufang Shi, Julia Bischof, Jonathan Woodsmith, Alessandro Anselmo, Gerry Melino, Giuseppe Tisone and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Mengting Zhu *Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.ORCID http://orcid.org/0000-0002-7891-9418
Valentina Rovella *Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.ORCID http://orcid.org/0000-0002-3311-486X
Manuel Scimeca *Department of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.ORCID http://orcid.org/0000-0003-0585-1309
Alessandro MaurielloDepartment of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.ORCID http://orcid.org/0000-0002-7351-5676
Yufang ShiThe Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Suzhou, 215000, China.ORCID http://orcid.org/0000-0001-8964-319X
Julia BischofIndivumed GmbH, Falkenried, 88 Building D, 20251, Hamburg, Germany.ORCID http://orcid.org/0000-0002-6672-6571
Jonathan WoodsmithIndivumed GmbH, Falkenried, 88 Building D, 20251, Hamburg, Germany.ORCID http://orcid.org/0000-0002-0790-3726
Alessandro AnselmoDepartment of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.ORCID http://orcid.org/0000-0003-1041-8120
Gerry MelinoDepartment of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy. melino@uniroma2.it.ORCID http://orcid.org/0000-0001-9428-5972
Giuseppe TisoneDepartment of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy. tisone@med.uniroma2.it.ORCID http://orcid.org/0000-0001-8860-5909
Massimiliano AgostiniDepartment of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy. m.agostini@med.uniroma2.it.ORCID http://orcid.org/0000-0003-3124-2072
University of Rome Tor Vergata · ITDermatologikum Hamburg · DESoochow University · CN

Funding

Associazione Italiana per la Ricerca contro il Cancro (AIRC) IG 2022 ID 27366; 2023-2027Ministero dell'Università e della Ricerca MUR-PNRR M4C2I1.3 PE6 project PE00000019 Heal ItaliaRegione Lazio LazioInnova Progetto Gruppo di Ricerca n 85-2017-14986; n 33 & 55-2021-T0002E0001
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, occurring predominantly in patients with underlying chronic liver disease and cirrhosis. Here, we describe a case of a 62-year-old man that was admitted to our hospital and diagnosed with HCC where the cancer has already metastasized to the retroperitoneum and peritoneum. In order to better characterize the HCC, both the cancerous liver tissue and the adjacent normal liver tissue of the patient were collected and subjected to a genomic, transcriptomic and proteomic analysis. Our patient carries a highly mutated HCC, which is characterized by both somatic mutation in the following genes ALK, CDK6, TP53, PGR. In addition, we observe several molecular alterations that are associated with potential therapy resistance, for example the expression of the organic-anion-transporting polypeptide (OATP) family members B1 and B3, that mediate the transport of the anticancer drugs, has been found decreased. Overall, our molecular profiling potentially classify the patient with poor prognosis and possibly displaying resistance to pharmacological therapy.

Identifiers

PMID38228856
PMCPMC10792141
OpenAlexW4390904045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.